Obsidian Therapeutics Inc. (OBX)
NASDAQ: OBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OBX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $741.29M
- EPS (TTM)
- -$6.52
- Dividend yield
- None
- 52-week range
- 9.60 – 49.97
- Day range
- 11.76 – 12.30
- Volume / Avg
- 336.50K / 511.50K
- Beta
- —
- Shares outstanding
- 61.77M
52-week range
OBX stock today
Shares of Obsidian Therapeutics (OBX) finished lower on Nov 20 at $12.00, a drop of 1.23% or $0.15 per share, versus the S&P 500's 3.70% decline. Shares are 76.0% below their 52-week high of $49.97, set on Aug 4, 2026 and 25.0% above the 52-week low of $9.60, near the bottom of the past year's range. Obsidian Therapeutics has posted a net loss over the last twelve months (EPS of -$6.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Obsidian Therapeutics
Company profileObsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Madan Jagasia M.D., M.S.
- Headquarters
- Cambridge, MA
- Employees
- 87
- Website
- obsidiantx.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$38.67+222.25%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.23 vs $-0.43
- Surprise
- -186.05%
OBX news
All OBX newsObsidian Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs OBX |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs OBX |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs OBX |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs OBX |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs OBX |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs OBX |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs OBX |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs OBX |
Indexes, lists and sector
Obsidian Therapeutics stock FAQ
What is Obsidian Therapeutics's stock price today?
OBX last traded at $12.00 as of Nov 20, 4:00 PM EST, down 1.23% on the day. Prices are delayed at least 15 minutes.
Who is Obsidian Therapeutics's CEO?
Dr. Madan Jagasia M.D., M.S. is the chief executive officer of Obsidian Therapeutics Inc., which has about 87 employees.
What is the OBX 52-week high?
The 52-week high for OBX is $49.97 and the 52-week low is $9.60. The stock is currently 76.0% below its high.